FDA Lifts Clinical Hold on Arbutus Biopharma's HBV Drug Candidate
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The U.S. Food and Drug Administration notified Arbutus Biopharma Corporation that the clinical hold on the Investigational New Drug application for AB-101 has been removed. This allows the company to proceed with additional clinical studies for AB-101 in the United States. AB-101 is an oral PD-L1 inhibitor being evaluated for chronic Hepatitis B Virus infection.
From thesudburystar.com
Why it matters
The removal of the clinical hold is a significant regulatory milestone for Arbutus Biopharma Corporation. The drug, AB-101, has already completed Phase 1a/1b trials, which showed it was generally well-tolerated and demonstrated evidence of hepatitis B surface antigen decline in some patients.
From thesudburystar.com
Who's involved
- FDARegulatory agency that removed the clinical hold on the drug application.
- United States of AmericaCountry where the clinical development may continue.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- CDER's drug evaluation process allows Arbutus Biopharma to advance its PD-L1 inhibitorCDER's drug evaluation process allows Arbutus Biopharma to advance its PD-L1 inhibitorAlready happening
- CBER's review pipeline advances with PD-L1 inhibitor clearanceArbutus Biopharma's PD-L1 inhibitor may advance through CBER's review process.Likely
Keep exploring
The entities involved
Related events
- FDA provided guidance for HCW Biologics' IND application.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Litigation regarding FDA approval process.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- FDA approval expands patient access to therapies for ACCORD.